Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ACHV 
Achieve Life Sciences Inc (ACHV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: ACHV (1-star) is a SELL. SELL since 3 days. Profits (6.04%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $16.71
1 Year Target Price $16.71
| 7 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -51.85% | Avg. Invested days 29 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 77.35M USD | Price to earnings Ratio - | 1Y Target Price 16.71 |
Price to earnings Ratio - | 1Y Target Price 16.71 | ||
Volume (30-day avg) 8 | Beta 1.64 | 52 Weeks Range 1.84 - 5.31 | Updated Date 06/30/2025 |
52 Weeks Range 1.84 - 5.31 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.35 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -59.02% | Return on Equity (TTM) -154.55% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 64080053 | Price to Sales(TTM) - |
Enterprise Value 64080053 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.42 | Shares Outstanding 34685100 | Shares Floating 29417797 |
Shares Outstanding 34685100 | Shares Floating 29417797 | ||
Percent Insiders 9.69 | Percent Institutions 41.59 |
Analyst Ratings
Rating 3 | Target Price 16.71 | Buy 1 | Strong Buy 7 |
Buy 1 | Strong Buy 7 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Achieve Life Sciences Inc
Company Overview
History and Background
Achieve Life Sciences Inc. is a pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and potentially other addictions. Founded in 1994 as New Leaf Bio, Inc., it later changed its name to Achieve Life Sciences.
Core Business Areas
- Smoking Cessation: Developing and commercializing cytisinicline, a plant-based compound with a long history of use in Central and Eastern Europe for smoking cessation.
Leadership and Structure
The leadership team includes executives with experience in pharmaceutical development, regulatory affairs, and commercialization. The organizational structure is typical of a clinical-stage biotech company focused on a single key asset.
Top Products and Market Share
Key Offerings
- Cytisinicline: Cytisinicline is Achieve's primary product, a plant-based smoking cessation aid. It is currently in Phase 3 clinical trials in the US and is already approved and marketed in some Eastern European countries. Competitors include nicotine replacement therapies (NRTs) from Johnson & Johnson (e.g., Nicorette), Pfizer's Chantix (varenicline), and bupropion (Zyban).
Market Dynamics
Industry Overview
The smoking cessation market is a large and growing market, driven by the health risks associated with smoking and increasing public health awareness. The market is competitive with a variety of pharmaceutical and non-pharmaceutical products.
Positioning
Achieve is positioned as a potential competitor to existing smoking cessation therapies, offering a different mechanism of action and a potentially more tolerable side effect profile.
Total Addressable Market (TAM)
The global smoking cessation market is estimated to be in the billions of dollars. Achieve is positioned to capture a share of this market with cytisinicline pending regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action for smoking cessation
- Clinical data demonstrating efficacy and safety
- Experienced management team
- Established manufacturing and supply chain
Weaknesses
- Reliance on a single product candidate
- Limited commercial infrastructure
- Need for regulatory approval in key markets like the US
- High cash burn rate
Opportunities
- Expansion into new markets beyond smoking cessation (e.g., other addictions)
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Increasing public awareness of the dangers of smoking
Threats
- Competition from existing smoking cessation therapies
- Regulatory hurdles and delays
- Patent challenges
- Adverse clinical trial results
Competitors and Market Share
Key Competitors
- JNJ
- PFE
Competitive Landscape
Achieve offers cytisinicline as a potential alternative with a unique mechanism of action. JNJ and PFE have already approved therapeutics and thus offer the advantage of market presence.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by advancement of the cytisinicline clinical program. R&D expenditure and staffing levels have been increased with the clinical milestones achieved
Future Projections: Future growth depends on the successful completion of clinical trials and regulatory approval of cytisinicline.
Recent Initiatives: Recent initiatives include the completion of Phase 3 clinical trials and preparation for regulatory submissions.
Summary
Achieve Life Sciences is a clinical-stage biotech company focused on cytisinicline for smoking cessation. The company's success hinges on positive clinical trial results and regulatory approval. It faces competition from established players but offers a novel therapeutic approach. Current investors need to consider the risk of the company continuing to have a high cash burn rate.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Achieve Life Sciences Inc
Exchange NASDAQ | Headquaters Bothell, WA, United States | ||
IPO Launch date 1995-10-13 | CEO & Executive Director Dr. Richard A. B. Stewart | ||
Sector Healthcare | Industry Biotechnology | Full time employees 25 | |
Full time employees 25 | |||
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.